UBS Asset Management Americas Inc. cut its position in uniQure NV (NASDAQ:QURE) by 3.8% during the second quarter, Holdings Channel reports. The fund owned 332,209 shares of the company’s stock after selling 13,194 shares during the period. UBS Asset Management Americas Inc. owned approximately 1.34% of uniQure NV worth $2,448,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock worth $104,000 after buying an additional 5,760 shares during the last quarter. Princeton Alpha Management LP purchased a new position in uniQure NV during the second quarter valued at $120,000. Fox Run Management L.L.C. purchased a new position in uniQure NV during the second quarter valued at $122,000. Quantitative Systematic Strategies LLC purchased a new position in uniQure NV during the second quarter valued at $165,000. Finally, Spark Investment Management LLC raised its position in uniQure NV by 28.1% in the first quarter. Spark Investment Management LLC now owns 296,000 shares of the company’s stock valued at $3,516,000 after buying an additional 64,900 shares in the last quarter. 32.38% of the stock is currently owned by hedge funds and other institutional investors.
uniQure NV (NASDAQ:QURE) traded down 0.596% during midday trading on Friday, reaching $7.505. The company’s stock had a trading volume of 26,790 shares. The firm’s market capitalization is $188.59 million. The stock has a 50 day moving average of $8.03 and a 200 day moving average of $10.00. uniQure NV has a 52 week low of $6.68 and a 52 week high of $22.79.
uniQure NV (NASDAQ:QURE) last posted its quarterly earnings results on Thursday, August 25th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.02. uniQure NV had a negative return on equity of 61.96% and a negative net margin of 537.62%. On average, equities research analysts predict that uniQure NV will post ($3.70) earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on QURE shares. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th. Leerink Swann reaffirmed a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a research note on Tuesday, June 14th. WallachBeth Capital reduced their price objective on uniQure NV from $60.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, June 15th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of uniQure NV in a research note on Wednesday, June 15th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $28.10.
uniQure NV Company Profile
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure NV (NASDAQ:QURE).
Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.